Erregierre
Erregierre is an Italian API manufacturer founded in 1974, producing small-molecule Active Pharmaceutical Ingredients for human and veterinary pharmaceutical companies across the US, EU, Japan, and South Korea from two Bergamo-cluster manufacturing sites.
- Company typePrivate
- Founded1974
- HeadquartersSan Paolo, Italy
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Erregierre does
Erregierre S.p.A. is an Italian Active Pharmaceutical Ingredient (API) manufacturer founded in 1974 by Pietro Gargani, specializing in the development and production of small-molecule APIs for both human and veterinary pharmaceutical use. The company operates from two manufacturing sites in the Bergamo pharmaceutical cluster in Northern Italy: a headquarters facility in San Paolo d'Argon and a second site in Sovere acquired in 2001, located approximately 20 miles apart for contingency planning. Combined capacity includes 55 glass-lined and stainless-steel reactors ranging from 70 to 10,000 liters, with a GMP-compliant pilot plant (70–700 L) for scale-up work, supported by R&D chemistry expertise across more than 40 reaction types including Grignard, Houben-Hoesch, Fischer indole synthesis, Friedel-Crafts acylations, and catalytic hydrogenations.
The company's product portfolio comprises over 40 human APIs across therapeutic categories (antihypertensives, antidepressants, antifungals, anticoagulants, antipsychotics, and others) and 17+ veterinary APIs covering antiparasitics (afloxerlaner, fluralaner, praziquantel), antiinflammatories (carprofen, deracoxib, firocoxib), and antifungals (clotrimazole, econazole nitrate). A development pipeline of newer molecules including Alogliptin Benzoate, Edoxaban Tosylate, and Brexpiprazole is offered at R&D sample or GMP scale. Products carry regulatory filings including US Type II DMFs, CEPs, Veterinary Master Files, and Japan Master Files, with 264 SOPs governing quality and operations.
Erregierre generates revenue through direct B2B sales of APIs under quote-based, multi-year contracts negotiated per project and volume, supplemented by regulatory support services for DMF and dossier submissions in the United States, Japan, South Korea, and Europe. The company serves branded and generic human pharmaceutical manufacturers and veterinary pharmaceutical companies globally, with first FDA audit completed in 1974 and ongoing regulatory maintenance (ISO 14001:2015, UNI ISO 45001:2018, Ecovadis Bronze). Distribution is entirely direct, with no public pricing disclosure and no disclosed external investors, parent company, or subsidiary structure.
Erregierre firmographics
Firmographics- Name
- Erregierre
- Legal name
- ERREGIERRE S.p.A.
- Website
- https://erregierre.it
- Company type
- Private
- Founded year
- 1974
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Erregierre is an Italian API manufacturer founded in 1974, producing small-molecule Active Pharmaceutical Ingredients for human and veterinary pharmaceutical companies across the US, EU, Japan, and South Korea from two Bergamo-cluster manufacturing sites.
- Ownership category
- akta.pro rank
Erregierre industry classification
Industry- Product category
- Active Pharmaceutical Ingredient (API) Manufacturing
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Small-Molecule API Commercial Manufacturing (HLAGAHAB)
Keywords
Where Erregierre is headquartered
LocationHeadquarters
- HQ city
- San Paolo
- HQ country
- Italy
- HQ region
- Europe
Offices2 records
Markets served
Erregierre business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Personnel, Technology or R&D, Infrastructure, Supply Chain, Others
Revenue model
- API Manufacturing and Supply: Erregierre manufactures and supplies Active Pharmaceutical Ingredients (APIs) to pharmaceutical companies. Revenue is generated through the sale of APIs for both human and veterinary use, with products covered by Drug Master Files (DMFs), CEPs, and regulatory approvals across multiple markets (US, EU, Japan, South Korea).
- Regulatory Support Services: The company provides regulatory support services for DMF and dossier submissions in highly regulated markets, helping clients achieve supply chain goals through expert regulatory consultation and submission services.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom API manufacturing contracts |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels2 records
Erregierre product offering
Product offeringCore offering
Erregierre manufactures and supplies Active Pharmaceutical Ingredients (APIs) for human and veterinary use, specializing in small-molecule APIs at medium-small volumes. The company operates two manufacturing sites in Northern Italy equipped with 55 reactors (70-10,000 L) and offers integrated capabilities from R&D chemistry and GMP pilot scale-up through commercial production, supported by regulatory filing expertise (DMFs, CEPs, VMFs, JMF) for the US, EU, Japan, and South Korea.
Product overview
Erregierre is a manufacturer of Active Pharmaceutical Ingredients (APIs) for human and veterinary pharmaceutical use, founded in 1974. The company offers a unified product-service portfolio comprising three main offerings: a Human API Portfolio of over 40 products with global regulatory approvals (EU, US, Japan, Korea), a Veterinary API Portfolio with VMF registrations, and an API Pipeline of products in development at R&D or GMP scale. These product lines are supported by integrated services including R&D Chemistry (with expertise in 30+ reaction types), a GMP Pilot Plant for scale-up validation, and Manufacturing Services across two facilities with 55 reactors totaling 70-10,000 liters capacity.
Differentiator
Problem solved
Functional benefit
Products and services
- Human API Portfolio A portfolio of over 40 Active Pharmaceutical Ingredients for human use across therapeutic classes including antihypertensives, antidepressants, antifungals, anticoagulants, antipsychotics, and treatments for Alzheimer's disease, with EU, US, and Japan regulatory approvals and corresponding DMF and CEP certifications.
- Veterinary API Portfolio A portfolio of Active Pharmaceutical Ingredients for veterinary use including antiparasitics (afloxerlaner, fluralaner), antiinflammatories (carprofen, deracoxib, firocoxib), antifungals (clotrimazole, econazole nitrate), and anthelmintics such as praziquantel, registered under Veterinary Master Files (VMF) at GMP scale.
- API Pipeline A pipeline of APIs in development or at R&D/GMP scale stage, including Alogliptin Benzoate, Edoxaban Tosylate, Brexpiprazole, and others, available as R&D samples or GMP scale for customers requiring early-stage supply.
- R&D Chemistry Services Chemical research and development services supporting new API project development, with expertise in 40+ reactions including Grignard, Friedel-Crafts, catalytic hydrogenations, oxidations, and specialized syntheses such as Hofmann rearrangement and Pictet-Spengler cyclization.
- Pilot Plant Services GMP-compliant pilot plant with synthesis and finishing areas, featuring 4 stainless steel and 3 enamelled reactors (70-700 L volume range), operating temperatures from -100°C to +180°C, operating pressure 1-8 bar, and equipment for vacuum drying, granulation, micronization, and dedicated packaging of liquid APIs.
- Manufacturing Services Full-scale API manufacturing from medium-small volumes across two sites (San Paolo d'Argon and Sovere) with 55 total reactors — stainless steel (70-10,000 L) and glass-lined (100-5,000 L) — supported by biological wastewater treatment and post-combustion emission control systems, enabling flexible commercial supply with contingency planning.
Quantifiable outcome
- 40% capacity increase following 2001 Sovere site acquisition
- +1 more outcomes
Companies that use Erregierre
Customer profileSegments2 records
Ideal customer profiles2 records
Erregierre technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Erregierre partnerships and signals
Strategic signalScale indicators9 records
Recent moves6 records
Expansion highlights4 records
Erregierre competitors and assessment
Company assessmentBroad incumbents
- Polpharma: Polish pharmaceutical manufacturer with vertically integrated API and finished dose operations. Comparable in API manufacturing scale and European regulatory depth, though broader in finished generics.
- Cambrex: US-headquartered global CDMO (now part of Permira portfolio) offering small-molecule API development and manufacturing at commercial scale. Larger incumbent with broader portfolio but overlapping in custom API manufacturing services.
- Chemo Group: Spanish-headquartered pharmaceutical group with API manufacturing operations serving generics and CDMO customers. Broader than Erregierre (includes finished dosage forms) but directly comparable in the small-molecule API manufacturing core.
- KRKA: Slovenian generic pharmaceutical company with in-house API manufacturing operations. Vertically integrated generic manufacturer with comparable API capability, primarily serving European markets.
Direct peers
- Olon: Italian-headquartered global CDMO/API manufacturer producing small-molecule APIs for generics and CDMO customers. Closest direct peer — same geography (Italian pharma cluster), same regulatory positioning (DMFs/CEPs), and overlapping therapeutic categories.
- Dipharma Francis: Italian API manufacturer headquartered near Bergamo, producing small-molecule APIs for human and veterinary generics. Direct competitor in same Italian pharma cluster with similar reactor scale and regulatory depth.
- Hovione: Portugal-based CDMO specializing in small-molecule API development and manufacturing for pharma customers globally. Comparable as a mid-sized, technology-driven API manufacturer with strong regulatory expertise in complex syntheses.
- Fabbrica Italiana Sintetici (FIS): Italian API manufacturer (now part of the ICI group) producing small-molecule active ingredients for the generic and CDMO markets. Same Italian base, same niche in complex small molecules, and overlapping customer base among European generic pharma.
Emerging players
- Zhejiang Huahai Pharmaceutical: Chinese API manufacturer with extensive US and EU DMF filings in cardiovascular, antiretrovirals, and central nervous system APIs. Represents the cost-competitive Asian pressure on European mid-tier API manufacturers like Erregierre.
- Aurobindo Pharma: Indian-headquartered global generic and API manufacturer. Competes in the same small-molecule API space at lower cost base, with growing regulatory depth in US/EU DMFs — a key threat and reference point for European mid-tier CDMOs.
Market position
Strengths5 records
Weaknesses3 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Erregierre social profiles
Digital presenceErregierre compliance and trust
Trust signalCompliance4 records
Erregierre financial estimates
Financial estimateRevenue estimate
Valuation estimate
Erregierre leadership team
Management profileNumber of profiles
Profiles1 record
Erregierre funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Erregierre M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Erregierre
What does Erregierre do?
Erregierre manufactures and supplies Active Pharmaceutical Ingredients (APIs) for human and veterinary use, specializing in small-molecule APIs at medium-small volumes. The company operates two manufacturing sites in Northern Italy equipped with 55 reactors (70-10,000 L) and offers integrated capabilities from R&D chemistry and GMP pilot scale-up through commercial production, supported by regulatory filing expertise (DMFs, CEPs, VMFs, JMF) for the US, EU, Japan, and South Korea.
Is Erregierre a public or private company?
Erregierre is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Erregierre founded?
Erregierre was founded in 1974. It employs 101 to 250 people.
Where is Erregierre based?
Erregierre is headquartered in San Paolo, Italy, in the Europe region.
How does Erregierre make money?
Two revenue lines are on record. API Manufacturing and Supply is the primary driver. The others are regulatory Support Services.
Who are Erregierre's main competitors?
Broad incumbents on record are Polpharma, Cambrex, Chemo Group and KRKA. Direct peers are Olon, Dipharma Francis, Hovione and Fabbrica Italiana Sintetici (FIS). Emerging players are Zhejiang Huahai Pharmaceutical and Aurobindo Pharma.
Does Erregierre have an API?
No public API is recorded for Erregierre.
What industry is Erregierre in?
Erregierre's product category is Active Pharmaceutical Ingredient (API) Manufacturing. Its primary akta.pro industry code is HLAGAHAB, Small-Molecule API Commercial Manufacturing. Its NAICS code is 3254 and its SIC code is 2834.